Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 1998 Mar 21;316(7135):894-8.

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration

Meta-Analysis

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration

Homocysteine Lowering Trialists’ Collaboration. BMJ. .

Abstract

Objective: To determine the size of reduction in homocysteine concentrations produced by dietary supplementation with folic acid and with vitamins B-12 or B-6.

Design: Meta-analysis of randomised controlled trials that assessed the effects of folic acid based supplements on blood homocysteine concentrations. Multivariate regression analysis was used to determine the effects on homocysteine concentrations of different doses of folic acid and of the addition of vitamin B-12 or B-6.

Subjects: Individual data on 1114 people included in 12 trials.

Findings: The proportional and absolute reductions in blood homocysteine produced by folic acid supplements were greater at higher pretreatment blood homocysteine concentrations (P < 0.001) and at lower pretreatment blood folate concentrations (P < 0.001). After standardisation to pretreatment blood concentrations of homocysteine of 12 mumol/l and of folate of 12 nmol/l (approximate average concentrations for Western populations), dietary folic acid reduced blood homocysteine concentrations by 25% (95% confidence interval 23% to 28%; P < 0.001), with similar effects in the range of 0.5-5 mg folic acid daily. Vitamin B-12 (mean 0.5 mg daily) produced an additional 7% (3% to 10%) reduction in blood homocysteine. Vitamin B-6 (mean 16.5 mg daily) did not have a significant additional effect.

Conclusions: Typically in Western populations, daily supplementation with both 0.5-5 mg folic acid and about 0.5 mg vitamin B-12 would be expected to reduce blood homocysteine concentrations by about a quarter to a third (for example, from about 12 mumol/l to 8-9 mumol/l). Large scale randomised trials of such regimens in high risk populations are now needed to determine whether lowering blood homocysteine concentrations reduces the risk of vascular disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reductions in blood homocysteine concentrations with folic acid supplements according to pretreatment blood concentrations of homocysteine, folate, and vitamin B-12. Squares indicate the ratios of post-treatment blood homocysteine among subjects allocated folic acid supplements to those of controls; size of square is proportional to number of subjects, and horizontal line indicates 95% confidence interval
Figure 2
Figure 2
Predicted proportional reduction in blood homocysteine concentrations with folic acid supplementation (0.5-5 mg daily)
Figure 3
Figure 3
Reductions in blood homocysteine concentrations with varying doses of folic acid at pretreatment blood concentrations of homocysteine of 12 μmol/l and folate of 12 nmol/l. Squares indicate the ratios of post-treatment blood homocysteine among subjects allocated folic acid supplements to those of controls; size of square is proportional to number of subjects, and horizontal line indicates 95% confidence interval

Similar articles

Cited by

References

    1. Boushey CJ, Beresford SA, Omen GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057. - PubMed
    1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155. - PubMed
    1. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–709. - PubMed
    1. Perry I, Refsum H, Morris RW, Ebrahim S, Ueland PM, Shaper AG. A prospective study of serum homocysteine concentration and risk of stroke in middle-aged men. Lancet. 1995;346:1395–1398. - PubMed
    1. Graham IM, Daly LE, Refsum H, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775–1781. - PubMed

Publication types